Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 881-890

  Gao, Wei ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GOTO KAKIZAKI RAT; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; INSULIN; MALE; MODELS, MOLECULAR; PEPTIDES; RATS; VENOMS;

EID: 79951962530     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175752     Document Type: Article

References (39)

1. Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, and Watada H (2009) Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem Biophys Res Commun 390:809-814.
2. Aziz A, Anderson GH, Giacca A, and Cho F (2005) Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides. Am J Physiol Regul Integr Comp Physiol 289:R688-R694. (Pubitemid 41208432)
3. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, and Parkes DG (2006) Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7:367-374.
4. Cvetković RS and Plosker GL (2007) Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 67:935-954. (Pubitemid 46607392)
5. D'Argenio DZ and Schumitzky A (1997) ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic System Analysis Software, Biomedical Simulations Resource, Los Angeles, CA.
6. Doyle ME and Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546-593. (Pubitemid 46365961)
7. Edholm T, Cejvan K, Abdel-Halim SM, Efendic S, Schmidt PT, and Hellström PM (2009) The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterol Motil 21:313-321.
8. Gao W, Bihorel S, Dubois DC, Almon RR, and Jusko WJ (2011) Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats. J Pharmacokinet Pharmacodyn doi:10.1002/bdd.738.
9. Gibiansky L, Gibiansky E, Kakkar T, and Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573-591.
10. Göke R, Larsen PJ, Mikkelsen JD, and Sheikh SP (1995) Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 62:130-134.
11. Goto Y, Suzuki K, Ono T, Sasaki M, and Toyota T (1988) Development of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol 246:29-31.
12. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, and Egan JM (1999) Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42: 45-50. (Pubitemid 29039736)
13. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, and Maggs DG (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286. (Pubitemid 351160260)
14. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, and Baron AD (2005) Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 62:173-181. (Pubitemid 40674548)
15. Landersdorfer CB and Jusko WJ (2008) Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet 47:417-448. (Pubitemid 351861956)
16. Larsen PJ, Tang-Christensen M, Holst JJ, and Orskov C (1997) Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257-270. (Pubitemid 27060323)
17. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, and Lins R (2007) Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64:317-327. (Pubitemid 47283860)
18. Mager DE, Abernethy DR, Egan JM, and Elahi D (2004) Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 311:830-835. (Pubitemid 39391573)
19. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532. (Pubitemid 34289541)
20. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518. (Pubitemid 36444157)
21. Ohara-Imaizumi M, Nishiwaki C, Kikuta T, Nagai S, Nakamichi Y, and Nagamatsu S (2004) TIRF imaging of docking and fusion of single insulin granule motion in primary rat pancreatic β-cells: different behaviour of granule motion between normal and Goto-Kakizaki diabetic rat β-cells. Biochem J 381:13-18. (Pubitemid 38932205)
22. Parkes DG, Pittner R, Jodka C, Smith P, and Young A (2001) Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50:583-589. (Pubitemid 32433049)
23. Pérez-Tilve D, González-Matías L, Aulinger BA, Alvarez-Crespo M, Gil-Lozano M, Alvarez E, Andrade-Olivie AM, Tschöp MH, D'Alessio DA, and Mallo F (2010) Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. Am J Physiol Endocrinol Metab 298:E1088-E1096.
24. Phillips A, Janssen U, and Floege J (1999) Progression of diabetic nephropathy. Insights from cell culture studies and animal models. Kidney Blood Press Res 22:81-97. (Pubitemid 29243450)
25. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, and Seeley RJ (2008) Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57:2046-2054.
26. Sato N, Komatsu K, and Kurumatani H (2003) Late onset of diabetic nephropathy in spontaneously diabetic GK rats. Am J Nephrol 23:334-342. (Pubitemid 37116933)
27. Satoh F, Beak SA, Small CJ, Falzon M, Ghatei MA, Bloom SR, and Smith DM (2000) Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology 141:1301-1309. (Pubitemid 32269096)
28. Schrijvers BF, De Vriese AS, Van de Voorde J, Rasch R, Lameire NH, and Flyvbjerg A (2004) Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes. Nephrol Dial Transplant 19:1092-1097. (Pubitemid 38628126)
29. Sharma A, Ebling WF, and Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577-1584. (Pubitemid 28559645)
30. Silber HE, Jauslin PM, Frey N, and Karlsson MO (2010) An integrated model for the glucose-insulin system. Basic Clin Pharmacol Toxicol 106:189-194.
31. Simonsen L, Pilgaard S, Orskov C, Hartmann B, Holst JJ, and Deacon CF (2009) Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats. Diabetes Obes Metab 11:884-890.
32. Simonsen L, Pilgaard S, Orskov C, Rosenkilde MM, Hartmann B, Holst JJ, and Deacon CF (2007) Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. Am J Physiol Gastrointest Liver Physiol 293: G288-G295. (Pubitemid 47105178)
33. Tornehave D, Kristensen P, Rømer J, Knudsen LB, and Heller RS (2008) Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56:841-851.
34. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, and Portha B (2002) Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443-1452. (Pubitemid 34826610)
35. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, et al. (2007) Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973. (Pubitemid 47481523)
36. Widmann C, Dolci W, and Thorens B (1995) Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. Biochem J 310:203-214.
37. Xu G, Stoffers DA, Habener JF, and Bonner-Weir S (1999) Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276. (Pubitemid 30395416)
38. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, and Denaro M (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034. (Pubitemid 29226349)
39. Zheng D, Ionut V, Mooradian V, Stefanovski D, and Bergman RN (2009) Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 58:352-359.